-
The rapid growth of new channel consumption will detonate the market for ginseng products!
Time of Update: 2022-10-25
Please pay attention to the selected video "Development Status and Trend Analysis of Ginseng Products in 2022" recently launched by the TCM Industry Big Data Platform of TNT-Cloud Map. The release of the "Healthy China 2030" Plan Outline in 2016 marked the elevation of "Healthy China" to a national strategy.
-
The third quarterly reports of listed pharmaceutical companies in 2022 have been disclosed one after another, and many results are good!
Time of Update: 2022-10-25
【Pharmaceutical Network Industry News】As of the close of trading on October 23, many A-share pharmaceutical companies, including Kangyuan Pharmaceutical, China Resources Sanjiu, and Laomin, released t
-
Observation of the third quarterly report: The pharmaceutical company's children's drug revenue increased, and its total revenue declined
Time of Update: 2022-10-25
However, from the perspective of product field division, the company's advantages in children's drug products initially appeared in the first three quarters of 2022, achieving operating income of 950 million yuan, a year-on-year increase of 17.
-
China's first mRNA vaccine was approved in Indonesia, and nearshore protein will explain the vaccine for you
Time of Update: 2022-10-25
In addition to raw material supply, nearshore protein is also developing mRNA stock solution preparation and detection processes to provide customers with more comprehensive services.
In addition to raw material supply, nearshore protein is also developing mRNA stock solution preparation and detection processes to provide customers with more comprehensive services.
-
Local API companies continue to have good news, which is related to the approval of products and the passage of inspection
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Recently, Tonghe Pharmaceutical issued an announcement that the APIs mirabelon and rivaroxaban passed the drug GMP (Good Manufacturing Practice) compliance inspection.
js?cdnversion='+~(-new Date()/36e5)]; Recently, Tonghe Pharmaceutical issued an announcement that the APIs mirabelon and rivaroxaban passed the drug GMP (Good Manufacturing Practice) compliance inspection.
-
Biomedical M&A will be active in 2022, and local pharmaceutical companies will increase their mergers and acquisitions of overseas companies!
Time of Update: 2022-10-25
For example, in October, Kyushu Pharmaceutical announced that it had decided to change the 185 million yuan raised in the fundraising and investment project to acquire 100% of Sandoz Zhongshan Pharmaceutical Factory and increase its capital.
-
NMPA Releases Administrative Measures for the Certification of Good Management Practices for Non-Clinical Research of Drugs (Draft for Comments)
Time of Update: 2022-10-25
Article 30 provincial-level drug regulatory department shall, in January of each year, report the routine supervision and inspection carried out in the previous year and the annual report of the GLP institution to the State Medical Products Administration and send a copy to the verification center.
-
Digital intelligence empowers Zhangshu, the "pharmaceutical capital of China" The annual revenue of the pharmaceutical industry exceeds 100 billion yuan
Time of Update: 2022-10-25
"We strive to build Geshushan Mountain Area into a national 5A-level tourist attraction in five years, develop a number of tourism commodities, traditional Chinese medicine meals and health foods with the characteristics of the medicine capital, and enhance the tourism image of 'China's medicine capital and health blessing land'.
-
More than 20 billion yuan of anti-anemia drug market, domestic pharmaceutical companies are actively layout
Time of Update: 2022-10-25
45 billion yuan in 2021, and it is expected that the scale of China's anti-anemia drug market will reach 26.
45 billion yuan in 2021, and it is expected that the scale of China's anti-anemia drug market will reach 26.
-
Macao hosted the 2022 Global Summit on the Digitalization of Traditional Chinese Medicine
Time of Update: 2022-10-25
(End) On October 21, the "9th Annual Conference of the Chinese Medicine Appraisal Professional Committee of the World Federation of Chinese Medicine Societies" and the "2022 Global Summit Forum on the Digitalization of Chinese Medicine" were officially opened in Macao.
-
Beijing: Strive to achieve direct inter-provincial settlement of general outpatient clinics within this year
Time of Update: 2022-10-25
5 billion yuan in drug costs。 The reporter recently learned from the Beijing Municipal Medical Security Bureau that by the end of this year, all designated medical institutions with the ability to receive treatment in the city will have full coverage of direct settlement of ordinary outpatient expenses across provinces.
-
East Sunshine's first generic patent challenged the original research successfully, and fingolimod capsules were approved for marketing in the United States
Time of Update: 2022-10-25
On October 18, 2022, the US court officially ruled that the US9187405 patent was invalid, and fingolimod capsules were officially put on sale in the United States, marking East Sunshine becoming the first Chinese company to challenge the original drug patent in the United States and succeed.
-
81 new Chinese medicine pieces will be included in the province's medical insurance payment coverage!
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; In recent years, traditional Chinese medicine has received different degrees of policy support in terms of strategic position, standardized development mode, price, payment end, medical insurance immunization, sales end and innovation rhythm.
-
Traditional Chinese medicinal materials in Yili Prefecture, Xinjiang have ushered in a one-year harvest period
Time of Update: 2022-10-21
On October 9, Yang Haihua, a villager in Wuzunbulak Town, Zhaosu County, Yili Prefecture, was busy digging for Chinese medicinal materials in the field: "Our family planted 400 acres of solitary work this year, and the overall growth is still relatively good, and the net income of about 400,000 yuan can be removed from the cost, and the benefits are still considerable.
-
State Food and Drug Administration: Guidelines for the verification of medical device registration quality management system
Time of Update: 2022-10-21
1 (Quality Management System) The registration applicant (hereinafter referred to as the applicant) shall, in accordance with the requirements of the Good Manufacturing Practice for Medical Devices and its appendices, establish a quality management system suitable for the product realization process based on scientific knowledge, experience and risk management principles, including commissioned production (if any), clinical evaluation (including clinical trials), etc.
-
Within half a month, a number of pharmaceutical companies approved their API products
Time of Update: 2022-10-20
On October 11, Lifang Pharmaceutical announced that the company recently received the "Acceptance Notice" for the marketing registration application of nifedipine API issued by the State Medical Products Administration.
-
After entering the "era of 10,000 stores", will the top chain pharmacies still make large-scale mergers and acquisitions?
Time of Update: 2022-10-20
js?cdnversion='+~(-new Date()/36e5)]; In recent years, the industry concentration of the pharmaceutical retail industry has been increasing, and in order to expand the scale of business, leading enterprises have accelerated the pace of horse racing through self-construction + mergers and acquisitions + joining.
-
Strictly control the cost of raw materials, Tasly's main business growth!
Time of Update: 2022-10-20
According to the 2022 half-year report of Tasly Pharmaceutical Group Co. , Ltd. (Tasly, 600535), the company achieved operating income of 4. 011 billion yuan in the first half of the year, a year-on-
-
In the 5G era, the development of pharmaceutical companies presses the "fast forward button"!
Time of Update: 2022-10-20
【Pharmaceutical Network Industry News】In the ointment production workshop of Ma Yinglong, a traditional Chinese medicine enterprise, through the application of 5G technology, almost all production pro
-
The development of First in class drugs also needs to meet unmet clinical needs
Time of Update: 2022-10-20
However, recently, the first in class diabetes drug "Dopagliatin Tablets" has fallen in stock price after being approved for marketing, which has aroused the attention of the industry.
